Source comparison
BPC-157 Osteoarthritis Mechanism: Research-Grade Comparison
Primary Action Upregulates VEGF, FGF-2; stimulates collagen synthesis and chondrocyte proliferation Inhibits COX-1/COX-2 enzymes to reduce prostaglandin synthesis Suppresses inflammatory gene transcription via glucocorticoid receptor binding BPC-157 is the onl
This comparison does not assign a generated winner or score.
- Primary Action
- Upregulates VEGF, FGF-2; stimulates collagen synthesis and chondrocyte proliferation
- Inhibits COX-1/COX-2 enzymes to reduce prostaglandin synthesis
- Suppresses inflammatory gene transcription via glucocorticoid receptor binding
- BPC-157 is the only intervention that targets tissue regeneration rather than symptom suppression
- Cartilage Repair
- Increases Type 1 collagen deposition by 58% in animal models; promotes proteoglycan synthesis
- No regenerative effect; long-term use may accelerate cartilage loss
- No regenerative effect; repeated injections linked to cartilage thinning
- BPC-157 demonstrates structural repair in controlled studies; NSAIDs and corticosteroids do not
- Inflammation Modulation
- Reduces TNF-α by 41%, IL-1β by 38%; inhibits NF-κB without affecting prostaglandins
- Broad suppression of prostaglandin synthesis; reduces pain and swelling
- Potent anti-inflammatory via cytokine suppression and immune cell inhibition
- All three reduce inflammation, but only BPC-157 does so without COX inhibition or immune suppression
- Side Effect Profile
- No gastric ulceration observed in 28-day rodent studies; minimal systemic effects
- GI bleeding, cardiovascular risk with long-term use; renal impairment in susceptible populations
- Immune suppression, hyperglycemia, osteoporosis with repeated use; cartilage degradation risk
- BPC-157 avoids the systemic toxicity that limits NSAIDs and corticosteroids for chronic use
- Evidence Base
- Animal studies only; no human clinical trials published as of 2026
- Extensive human trial data; FDA-approved for osteoarthritis symptom management
- Extensive human trial data; FDA-approved for intra-articular injection
- BPC-157 lacks human efficacy data. Its use remains limited to research settings